Wendy's on Thursday rejected a $1.4 billion takeover offer from a group led by Nelson Peltz's Trian Fund Management. The bid, made at $7.35 per share in cash on Oct. 28, would have taken the struggling burger chain private. The company's independent committee concluded that the proposal "substantially undervalues" Wendy's and does not reflect potential gains from its ongoing turnaround strategy. On the narrow question of price, that conclusion deserves a hearing from anyone who owns the stock.

The offer came from more than Trian alone. Investment firms BlueFive Capital and Sixth Street Partners joined, along with Flynn Group, one of Wendy's largest franchisees. A franchisee sitting on the buyer side raises obvious questions about whose interests a deal would serve. Those questions are not answered by the bid price alone, and the board was right to examine them through a committee of independent directors formed in February.

The board's response also included a shareholder rights plan, or poison pill, with a one-year duration. Wendy's said the Trian-led group had rejected its offer of a standstill agreement that would have paused additional share purchases. Adopting a poison pill is a defensive tool, and it should be judged by whether it protects shareholders from a low bid or simply entrenches management. A one-year term is a reasonable sign that the board intends it as a temporary shield rather than a permanent wall.

The harder problem is performance. Wendy's same-store sales declined for a seventh straight quarter, even as third-quarter earnings and revenue beat Wall Street's expectations. The stock has lost about 60% of its value over the last three years. Shares fell less than 1% in morning trading after the rejection, a modest move that suggests investors see the board's position as a reasonable bet but not a guaranteed one. Chairman Art Winkleblack pointed to CEO Bob Wright's record in restaurant turnarounds. That record now has to show up in the sales numbers.

My advice to the board is simple. Rejecting Trian was defensible. Now it should publish concrete turnaround targets, with timelines for same-store sales recovery and clear metrics that shareholders can track each quarter. Trian's history with the company, including its 2008 purchase of Wendy's in a $2.3 billion deal, means the board should expect continued pressure and answer it with results rather than rhetoric. A poison pill can buy time, but it cannot substitute for a plan that makes the stock worth holding.